HTA and Reimbursement Submissions

Get Prepared for EU Joint Clinical Assessment

Our experts are here to help pharma and medtech companies prepare for JCA with a suite of strategic and technical services. Learn more.

The reimbursement environment is constantly changing. Requirements vary between markets and need coordination across multiple areas to produce high-quality results. To help you achieve market access, our experts across our health economics and market access and outcomes strategy teams have experience contributing to successful submissions in many countries and across therapeutic areas. Our integrated team approach can help you achieve the best result for your product.

We can support you in any aspects of research and product development you require for your reimbursement submissions.

Our experience includes:

Our track record of successfully supporting submissions in major markets includes the following:

  • Australia:  PBAC 
  • Canada: CADTH, INESSS
  • Denmark: DMC, Amgros, DMA
  • Finland: Fimea, Hila
  • Germany: AMNOG
  • Norway: NoMa
  • Republic of Ireland:  NCPE
  • Sweden: TLV
  • United Kingdom: NICE, SMC, AWMSG

In addition to global HTA submissions, we routinely perform the full package of research underpinning AMCP dossiers and preparation for ICER engagements to support launches in the US.